Price
No data yet.
Social Signal Score
Revenue
$256.15M+166.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph K. Belanoff
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 730
- Beta
- 0.46
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 44.32
Financials
Revenue
$256.15M+166.5%Net Income
$42.14M+38.3%EBITDA
$46.79M+26.2%Free Cash Flow
$31.02M-36.1%EPS (diluted)
$0.36+50.0%Shares Outstanding (diluted)
118.39M-5.4%Operating Expenses
$210.79MCash & Debt
$308.20MReturn of Capital
$11.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $761.41M | $99.65M | $0.95 |
| 2024 | $675.04M | $139.73M | $1.35 |
| 2023 | $482.38M | $106.14M | $1.02 |
| 2022 | $401.86M | $101.42M | $0.95 |
| 2021 | $365.98M | $112.51M | $0.97 |
| 2020 | $353.87M | $106.01M | $0.92 |
| 2019 | $306.49M | $94.18M | $0.82 |
| 2018 | $251.25M | $75.41M | $0.60 |
| 2017 | $159.20M | $129.12M | $1.14 |
| 2016 | $81.32M | $8.14M | $0.07 |
| 2015 | $50.29M | $-6.41M | $-0.06 |
| 2014 | $26.55M | $-31.38M | $-0.31 |
| 2013 | $10.36M | $-46.01M | $-0.46 |
| 2012 | $3.31M | $-38.05M | $-0.41 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.41
- Implied price
- $52.16
- Return from $118.10
- -15.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.93 — -78.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 31 | 37 | 43 | 49 |
|---|---|---|---|---|---|
| -2.0% | -28.8% | -25.6% | -22.9% | -20.6% | -18.5% |
| 3.0% | -25.1% | -21.8% | -19.0% | -16.5% | -14.3% |
| 8.0% | -21.5% | -18.0% | -15.1% | -12.5% | -10.2% |
| 13.0% | -17.8% | -14.2% | -11.1% | -8.4% | -6.0% |
| 18.0% | -14.2% | -10.4% | -7.2% | -4.4% | -1.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsfinbold.com·1d ago·Neutral
Trump is up 230% on this stock trade since March President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
View source ↗
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.65 per share
Typical surprise -11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.36 vs $0.02beat
- Thu, Apr 30$-0.30 vs $-0.11miss
- Tue, Feb 24$0.20 vs $0.33miss
- Tue, Nov 4$0.16 vs $0.18miss
- Thu, Jul 31$0.29 vs $0.23beat
- Mon, May 5$0.17 vs $0.17beat
Estimates and results for CORT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CORT officers and directors.
- Bought
- —
- Sold
- $38.2m
0 trades
50 trades
- Robb Gary Charlessold
- Maduck Seansold
- Wilson James Nsold
- Wilson James Nsold
- Wilson James Nsold
- Maduck Seansold
- Guyer Williamsold
- Guyer Williamsold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.